Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paeoniflorin + cervus and cucumis polypeptide
- Development stage
- Unknown
- Modality
- Small Molecules, Peptides
- Administration
- Intramuscular, Oral
01
Overview
A traditional Chinese medicine combination used primarily for treating rheumatoid arthritis. The formulation consists of paeoniflorin (PAE), which has anti-inflammatory properties, and cervus and cucumis polypeptide injection (CCPI), which has bone healing, pain relieving, and anti-inflammatory properties. Clinical studies indicate that while this combination may not be as effective as conventional disease-modifying antirheumatic drugs (DMARDs) for long-term treatment of rheumatoid arthritis, it appears to have a faster onset of action and fewer adverse effects.
- Brand names
- Pafulin + Songmeile
- Other names
- PAE + CCPI
02
Targets
TLR (Toll-like receptors)
Beyond the preview
Go deeper on paeoniflorin + cervus and cucumis polypeptide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paeoniflorin + cervus and cucumis polypeptide.